ᱯᱷᱟᱭᱡᱟᱨ-ᱵᱟᱭᱳᱮᱱᱴᱮᱠ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ

ᱯᱷᱟᱭᱡᱟᱨ-ᱵᱟᱭᱳᱮᱱᱴᱮᱠ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ
INN: tozinameran
	A vial of the Pfizer–BioNTech COVID‑19 vaccine for the U.S. market
ᱴᱤᱠᱟᱹ ᱨᱮᱭᱟᱜ ᱵᱚᱨᱱᱚᱱ
ᱡᱚᱥ ᱟᱡᱟᱨ	SARS-CoV-2
ᱞᱮᱠᱟᱱ	mrna
ᱠᱞᱤᱱᱤᱠᱟᱞ ᱰᱮᱴᱟ
ᱨᱟᱹᱲ	Tozinameran: /ˌtoʊzɪˈnæmərən/ TOH-zih-NAM-ər-ən; Comirnaty: /koʊˈmɜːrnəti/ koh-MUR-nə-tee
ᱵᱮᱯᱟᱨ ᱧᱩᱛᱩᱢᱠᱚ	Comirnaty
ᱮᱴᱟᱜ ᱧᱩᱛᱩᱢ	BNT162b2, COVID-19 mRNA vaccine (nucleoside-modified)
ᱮ.ᱮᱭᱤᱪ.ᱮᱯᱷ.ᱮᱥ/ᱰᱨᱟᱜᱥ.ᱠᱚᱢ	Multum Consumer Information
ᱢᱮᱰᱞᱟᱭᱤᱱᱯᱞᱟᱥ	a621003
ᱰᱮᱴᱟ	EU EMA: yes; US DailyMed: Pfizer–BioNTech_COVID-19_Vaccine;
ᱦᱚᱲᱢᱚᱜ; ᱛᱷᱚᱠ	AU: B1 ; ;
ᱵᱮᱵᱷᱟᱨ ᱨᱮᱱᱟᱜ; ᱴᱷᱟᱶ	Intramuscular
ᱮ.ᱴᱤ.ᱥᱤ ᱠᱳᱰ	None;
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ
ᱟᱹᱱᱟᱹᱨᱤ ᱦᱟᱞᱚᱛ	AU: S4 (Prescription only) ; CA: Schedule D ; UK: Conditional and temporary authorization to supply ; US: ℞-only with standing order; Approved for those aged 16+; Emergency Use Authorization for those aged 12–15; EU: Conditional marketing authorization granted ; CH: Rx-only[further explanation needed]; ZA: Section 21 Others: List of Pfizer-BioNTech COVID-19 vaccine authorizations
ᱩᱯᱨᱩᱢᱤᱭᱟᱹ
ᱥᱤ.ᱮ.ᱮᱥ ᱱᱚᱢᱵᱚᱨ	2417899-77-3;
ᱯᱟᱵᱽᱠᱮᱢ ᱥᱮ.ᱟᱭ.ᱰᱤ	434370509;
ᱰᱨᱟᱜᱵᱮᱸᱠ	DB15696;
ᱭᱩ.ᱮᱱ.ᱟᱭ.ᱟᱭ	5085ZFP6SJ;
ᱠᱮ.ᱤ.ᱡᱤ.ᱡᱤ	D11971;

ᱯᱷᱟᱭᱡᱟᱨ-ᱵᱟᱭᱳᱮᱱᱴᱮᱠ ᱠᱳᱵᱷᱤᱰ-᱑᱙ ᱴᱤᱠᱟᱹ ᱫᱚ ᱯᱷᱟᱭᱡᱟᱨᱟᱜ ᱜᱚᱸᱲᱚᱸ ᱛᱮ ᱵᱟᱭᱳᱮᱱᱴᱮᱠ ᱟᱜ ᱵᱮᱱᱟᱣᱟᱜ ᱢᱤᱫ ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱥᱟᱝᱠᱮᱛᱤᱠ ᱧᱩᱛᱩᱢ ᱫᱚ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ ᱵᱤᱮᱱᱴᱤ᱑᱖᱒ᱵᱤ᱒᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱫᱚ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱛ ᱟᱹᱭᱫᱟᱹᱨᱤ ᱧᱟᱢ ᱟᱠᱟᱫ ᱯᱟᱹᱦᱤᱞ ᱩᱛᱟᱹᱨ ᱴᱤᱠᱟᱹ ᱠᱟᱱᱟ᱾

ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱫᱚ ᱦᱚᱲᱢᱚ ᱨᱮᱱᱟᱜ ᱥᱚᱯᱚ ᱨᱮᱠᱚ ᱮᱢᱟ᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱫᱚ ᱵᱟᱨᱮᱭᱟ ᱰᱳᱡᱽ ᱠᱳ ᱮᱢᱚᱜᱼᱟ᱾ ᱯᱟᱹᱦᱤᱞ ᱰᱳᱡᱽ ᱮᱢ ᱯᱮᱦᱟᱯᱛᱟ ᱛᱟᱭᱚᱢ ᱫᱚᱥᱟᱨ ᱰᱳᱡᱽ ᱦᱟᱛᱟᱣ ᱦᱩᱭᱩᱜᱼᱟ᱾ ᱜᱤᱫᱽᱨᱟᱹ ᱦᱚᱲ ᱟᱨ ᱞᱟᱡ ᱨᱮ ᱜᱤᱫᱽᱨᱟᱹ ᱢᱮᱱᱟᱜ ᱛᱟᱹᱠᱩ ᱟᱭᱳ ᱦᱚᱲ ᱞᱟᱹᱜᱤᱛ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱛᱤᱱᱟᱹᱜ ᱮ ᱠᱟᱹᱢᱤ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ ᱚᱱᱟ ᱫᱚ ᱵᱟᱝ ᱵᱟᱰᱟᱭ ᱧᱟᱢ ᱟᱠᱟᱱᱟ᱾

᱒᱐᱒᱐ ᱥᱮᱨᱢᱟ ᱨᱮᱱᱟᱜ ᱮᱯᱨᱤᱞ ᱪᱟᱸᱫᱚ ᱠᱷᱚᱱ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱨᱮᱱᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱮᱛᱦᱚᱵ ᱟᱠᱟᱱᱟ᱾ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱦᱟᱛᱟᱣ ᱠᱟᱛᱮ ᱥᱚᱯᱚ ᱨᱮ ᱱᱟᱥᱮᱭᱟᱜ ᱦᱟᱥᱚ, ᱵᱚᱦᱚᱜ ᱦᱟᱥᱚ ᱟᱨ ᱞᱟᱸᱜᱟᱸᱢ ᱟᱹᱭᱠᱟᱹᱣ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾ ᱛᱚᱵᱮ ᱱᱤᱛ ᱫᱷᱟᱹᱵᱤᱡ ᱱᱚᱣᱟ ᱴᱤᱠᱟᱹ ᱦᱟᱛᱟᱣ ᱦᱚᱲ ᱫᱚ ᱟᱹᱰᱤ ᱵᱟᱹᱲᱤᱡ ᱡᱟᱸᱦᱟᱸ ᱨᱩᱣᱟᱹ ᱦᱟᱥᱚ ᱫᱚ ᱵᱟᱝ ᱧᱟᱢ ᱟᱠᱟᱫ ᱠᱩᱣᱟ᱾

ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ

↑ "Comirnaty". Therapeutic Goods Administration (TGA). 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
↑ ^᱒.᱐ ^᱒.᱑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named Swiss authorization
↑ ^᱓.᱐ ^᱓.᱑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named Comirnaty EPAR
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named Comirnaty global
↑ ^᱕.᱐ ^᱕.᱑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named FDA PR 20210823
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named fiercepharma
↑ "Comirnaty (BNT162b2 [mRNA]) COVID-19 Vaccine Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 2 February 2021. Retrieved 25 January 2021.
↑ Australian Public Assessment Report for BNT162b2 (mRNA) (PDF) (Report). Therapeutic Goods Administration (TGA). Archived (PDF) from the original on 26 January 2021. Retrieved 25 January 2021.
↑ "Vacina da Pfizer é a 1ª contra a Covid a obter registro definitivo no Brasil". G1 (in ᱵᱨᱟᱡᱤᱞᱤᱭᱟᱱ ᱯᱩᱨᱛᱜᱟᱞᱤ). 23 February 2021. Archived from the original on 17 March 2021. Retrieved 20 March 2021.
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA Regulatory Decision Summary - Comirnaty
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA Comirnaty
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA COVID-19 authorizations
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named MHRA product information
↑ "Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2020. Archived from the original on 26 February 2021. Retrieved 8 January 2021.
↑ "Pfizer-Biontech COVID-19 Vaccine- bnt162b2 injection, suspension". DailyMed. Archived from the original on 29 January 2021. Retrieved 14 December 2020.
↑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named FDA EUA letter
↑ "Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" (PDF). Centers for Disease Control and Prevention (CDC). Archived (PDF) from the original on 14 August 2021. Retrieved 13 August 2021.
↑ "South Africa approves Pfizer Covid-19 vaccine for emergency use". Archived from the original on 18 March 2021. Retrieved 18 March 2021.
↑ Nkanjeni U. "Pfizer-BioNTec approved for emergency use in SA: here is what you need to know about the vaccine". TimesLIVE. Archived from the original on 19 April 2021. Retrieved 19 March 2021.

[1] "Comirnaty". Therapeutic Goods Administration (TGA). 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.

[Swiss_authorization-2] ᱒.᱐ ^᱒.᱑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named Swiss authorization

[Comirnaty_EPAR-3] ᱓.᱐ ^᱓.᱑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named Comirnaty EPAR

[Comirnaty_global-4] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named Comirnaty global

[FDA_PR_20210823-5] ᱕.᱐ ^᱕.᱑ ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named FDA PR 20210823

[fiercepharma-6] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named fiercepharma

[7] "Comirnaty (BNT162b2 [mRNA]) COVID-19 Vaccine Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 2 February 2021. Retrieved 25 January 2021.

[8] Australian Public Assessment Report for BNT162b2 (mRNA) (PDF) (Report). Therapeutic Goods Administration (TGA). Archived (PDF) from the original on 26 January 2021. Retrieved 25 January 2021.

[9] "Vacina da Pfizer é a 1ª contra a Covid a obter registro definitivo no Brasil". G1 (in ᱵᱨᱟᱡᱤᱞᱤᱭᱟᱱ ᱯᱩᱨᱛᱜᱟᱞᱤ). 23 February 2021. Archived from the original on 17 March 2021. Retrieved 20 March 2021.

[CA_Regulatory_Decision_Summary_-_Comirnaty-10] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA Regulatory Decision Summary - Comirnaty

[CA_Comirnaty-11] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA Comirnaty

[CA_COVID-19_authorizations-12] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named CA COVID-19 authorizations

[MHRA_product_information-13] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named MHRA product information

[14] "Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2020. Archived from the original on 26 February 2021. Retrieved 8 January 2021.

[Pfizer-BioNTech_COVID-19_Vaccine_FDA_label-15] "Pfizer-Biontech COVID-19 Vaccine- bnt162b2 injection, suspension". DailyMed. Archived from the original on 29 January 2021. Retrieved 14 December 2020.

[FDA_EUA_letter-16] ᱛᱩᱢᱟᱹᱞ ᱦᱩᱲᱟᱹᱜ:Invalid <ref> tag; no text was provided for refs named FDA EUA letter

[CDC_standing_order-17] "Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" (PDF). Centers for Disease Control and Prevention (CDC). Archived (PDF) from the original on 14 August 2021. Retrieved 13 August 2021.

[businesstech.co.za-18] "South Africa approves Pfizer Covid-19 vaccine for emergency use". Archived from the original on 18 March 2021. Retrieved 18 March 2021.

[19] Nkanjeni U. "Pfizer-BioNTec approved for emergency use in SA: here is what you need to know about the vaccine". TimesLIVE. Archived from the original on 19 April 2021. Retrieved 19 March 2021.

[᱖]

[᱒]

[᱓]

[᱔]

[᱕]

[᱑]

[᱗]

[᱘]

[᱑᱐]

[᱑᱑]

[᱑᱒]

[᱑᱓]

[᱑᱔]

[᱑᱕]

[᱑᱖]

[᱑᱗]

[᱑᱘]

[᱑᱙]